New research shows that people diagnosed with a genetic condition, called alpha-1 antitrypsin deficiency (AATD), are far more likely to stop smoking and therefore prevent the development of lung disease.
The study, led by researchers from RCSI University of Medicine and Health Science, is published in COPD: Journal of Chronic Obstructive Pulmonary Disease.
It is estimated that 265,000 people on the island of Ireland are affected by either severe or moderate AATD, but the vast majority of people with AATD have not been diagnosed.
Previously, it was assumed that only people with severe AATD were at risk of lung disease. Recent Irish research has shown that people with the far more common moderate form of AATD are also at risk of lung disease if they are smokers.
With the smoking rate in the general population in Ireland at 17%, this means there are approximately 45,000 current smokers with either severe or moderate AATD who are at increased risk of lung damage due to cigarettes. According to the latest figures from the national targeted detection programme for AATD based at RCSI Beaumont Hospital, 90% of these smokers with AATD remain undiagnosed.
The researchers surveyed patients enrolled in the National AATD Registry with a questionnaire relating to demographics, parental smoking history, personal smoking history, AATD awareness and personal medical history.
Of the 293 respondents, 58 reported being smokers at the time of their AATD diagnosis. Their subsequent reported quit rate was 70.7%.
"Our study has shown that those who receive a diagnosis of alpha-1 antitrypsin deficiency are far more likely to stop smoking. We hope this study will lead to increased testing for AATD, with more people being diagnosed and choosing to stop or completely avoid smoking in order to prevent lung disease from developing," said Dr Tomás Carroll, senior lecturer at RCSI and the study's corresponding author.
"People with AATD who use electronic cigarettes are also potentially at risk, but more research is needed."
The research also found that people who reported having a parent who smoked were far more likely to become smokers themselves. Those with a parent who smoked were 84% more likely to smoke than those who did not.
For a diagnosis of AATD, a simple blood test is available in most large hospitals in Ireland that can identify those who need further testing. The more precise definitive test is provided for free by Alpha-1 Foundation Ireland as part of a HSE funded national targeted detection programme.
More information on how to get tested can be found at http://www.
AATD results from a deficiency of the alpha-1 antitrypsin protein, which is made by the liver and protects tissues in the body from being attacked by its own enzymes. It is a genetic condition that can cause lung, liver and skin disease.
With 1 in 25 people in Ireland carrying a defective alpha-1 antitrypsin gene, AATD is much more common in Ireland than in most other countries. AATD is one of the most common genetic conditions in Ireland.
About RCSI University of Medicine and Health Sciences
Ranked number one globally for Good Health and Well-being in the Times Higher Education (THE) University Impact Rankings 2020, RCSI University of Medicine and Health Sciences is an international not-for-profit university, with its headquarters in Dublin.
RCSI is exclusively focused on education and research to drive improvements in human health worldwide. It is among the top 250 universities worldwide in the THE World University Rankings (2020) and its research is ranked first in Ireland for citations. RCSI has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education.
Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise.